{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,13]],"date-time":"2026-01-13T16:46:13Z","timestamp":1768322773081,"version":"3.49.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,3,1]],"date-time":"2012-03-01T00:00:00Z","timestamp":1330560000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Research in Social and Administrative Pharmacy"],"published-print":{"date-parts":[[2012,3]]},"DOI":"10.1016\/j.sapharm.2010.12.004","type":"journal-article","created":{"date-parts":[[2011,6,30]],"date-time":"2011-06-30T00:34:58Z","timestamp":1309394098000},"page":"157-165","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Does combining antiretroviral agents in a single dosage form enhance quality of life of HIV\/AIDS patients? A cost-utility study"],"prefix":"10.1016","volume":"8","author":[{"given":"Arijit","family":"Ganguli","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junling","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dick R.","family":"Gourley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.sapharm.2010.12.004_bib1","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1097\/01.mlr.0000228021.89490.2a","article-title":"The lifetime cost of current human immunodeficiency virus care in the US","volume":"44","author":"Schackman","year":"2006","journal-title":"Med Care"},{"key":"10.1016\/j.sapharm.2010.12.004_bib2","first-page":"589","article-title":"Epidemiology of HIV\/AIDS-US, 1981-2005","volume":"55","author":"Center for Disease Control and Prevention","year":"2006","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.sapharm.2010.12.004_bib3","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1592\/phco.26.8.1111","article-title":"An update and review of antiretroviral therapy","volume":"26","author":"Piacenti","year":"2006","journal-title":"Pharmacotherapy"},{"issue":"suppl 1","key":"10.1016\/j.sapharm.2010.12.004_bib4","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1097\/QAI.0b013e3180600766","article-title":"The role of adherence to antiretroviral therapy in the management of HIV infection","volume":"45","author":"Conway","year":"2007","journal-title":"J\u00a0Acquir Immune Defic Syndr"},{"key":"10.1016\/j.sapharm.2010.12.004_bib5","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1097\/01.qai.0000182847.38098.d1","article-title":"Discordant immunologic and virologic responses to highly active antiretroviral therapy are associated with increased mortality and poor adherence to therapy","volume":"40","author":"Moore","year":"2005","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.sapharm.2010.12.004_bib6","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1097\/00126334-200403010-00006","article-title":"The impact of adherence on CD4 cell count responses among HIV-infected patients","volume":"35","author":"Wood","year":"2004","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.sapharm.2010.12.004_bib7","doi-asserted-by":"crossref","first-page":"810","DOI":"10.7326\/0003-4819-139-10-200311180-00008","article-title":"Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 \u00d7 10(9) cells\/L","volume":"139","author":"Wood","year":"2003","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.sapharm.2010.12.004_bib8","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1086\/338255","article-title":"Daily dosing of highly active antiretroviral therapy","volume":"34","author":"Rosenbach","year":"2002","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.sapharm.2010.12.004_bib9","first-page":"320","article-title":"Impact of once- and twice-daily dosing regimens on adherence and overall safety","volume":"14","author":"Hawkins","year":"2004","journal-title":"AIDS Read"},{"key":"10.1016\/j.sapharm.2010.12.004_bib10","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/j.1468-1293.2005.00287.x","article-title":"Better maintained adherence on switching from twice-daily to once-daily therapy for HIV: a 24-week randomized trial of treatment simplification using stavudine prolonged-release capsules","volume":"6","author":"Portsmouth","year":"2005","journal-title":"HIV Med"},{"key":"10.1016\/j.sapharm.2010.12.004_bib11","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/QAI.0b013e3181a572cf","article-title":"Simplification of antiretroviral therapy to a single-tablet regimen consisting of efavirenz, emtricitabine, and tenofovir disoproxil fumarate versus unmodified antiretroviral therapy in virologically suppressed HIV-1-infected patients","volume":"51","author":"Dejesus","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.sapharm.2010.12.004_bib12","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1089\/apc.2009.0259","article-title":"Patient-reported outcomes in virologically suppressed, HIV-1-infected subjects after switching to a simplified, single-tablet regimen of efavirenz, emtricitabine, and tenofovir DF","volume":"24","author":"Hodder","year":"2010","journal-title":"AIDS Patient Care STDS"},{"key":"10.1016\/j.sapharm.2010.12.004_bib13","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1310\/hct0902-103","article-title":"Impact of switching virologically suppressed, HIV-1-infected patients from twice-daily fixed-dose zidovudine\/lamivudine to once-daily fixed-dose tenofovir disoproxil fumarate\/emtricitabine","volume":"9","author":"DeJesus","year":"2008","journal-title":"HIV Clin Trials"},{"key":"10.1016\/j.sapharm.2010.12.004_bib14","first-page":"115","article-title":"One-pill once-a-day HAART: a simplification strategy that improves adherence and quality of life of HIV-infected subjects","volume":"4","author":"Airoldi","year":"2010","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.sapharm.2010.12.004_bib15","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1097\/01.mlr.0000135827.18610.0d","article-title":"The estimation of a preference-based measure of health from the SF-12","volume":"42","author":"Brazier","year":"2004","journal-title":"Med Care"},{"key":"10.1016\/j.sapharm.2010.12.004_bib16","doi-asserted-by":"crossref","first-page":"1440","DOI":"10.1136\/bmj.306.6890.1440","article-title":"The SF-36 health survey questionnaire: an outcome measure suitable for routine use within the NHS","volume":"306","author":"Garratt","year":"1993","journal-title":"BMJ"},{"key":"10.1016\/j.sapharm.2010.12.004_bib17","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0167-6296(01)00130-8","article-title":"The estimation of a preference-based measure of health from the SF-36","volume":"21","author":"Brazier","year":"2002","journal-title":"J Health Econ"},{"key":"10.1016\/j.sapharm.2010.12.004_bib18","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1097\/00005650-200307000-00003","article-title":"Variation in the estimation of quality-adjusted life-years by different preference-based instruments","volume":"41","author":"Conner-Spady","year":"2003","journal-title":"Med Care"},{"key":"10.1016\/j.sapharm.2010.12.004_bib19","author":"MEPS"},{"key":"10.1016\/j.sapharm.2010.12.004_bib20","author":"US FDA"},{"key":"10.1016\/j.sapharm.2010.12.004_bib21","author":"HAART Chart"},{"key":"10.1016\/j.sapharm.2010.12.004_bib22","first-page":"27","article-title":"A comparison of SF-6D and EQ-5D utility scores in a study of patients with schizophrenia","volume":"12","author":"McCrone","year":"2009","journal-title":"J Ment Health Policy Econ"},{"key":"10.1016\/j.sapharm.2010.12.004_bib23","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/bimj.200810488","article-title":"Some methods of propensity-score matching had superior performance to others: results of an empirical investigation and Monte Carlo simulations","volume":"51","author":"Austin","year":"2009","journal-title":"Biom J"},{"key":"10.1016\/j.sapharm.2010.12.004_bib24","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.jclinepi.2004.10.016","article-title":"Propensity score methods gave similar results to traditional regression modeling in observational studies: a systematic review","volume":"58","author":"Shah","year":"2005","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.sapharm.2010.12.004_bib25","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1002\/hec.635","article-title":"Representing uncertainty: the role of cost-effectiveness acceptability curves","volume":"10","author":"Fenwick","year":"2001","journal-title":"Health Econ"},{"key":"10.1016\/j.sapharm.2010.12.004_bib26","first-page":"3919","article-title":"An approximation of skewed healthcare expenditure distribution using mixed model","author":"William","year":"2005","journal-title":"American Statistical Association Section on Survey Research Methods"},{"key":"10.1016\/j.sapharm.2010.12.004_bib27","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1586\/14737167.8.2.165","article-title":"Assessing cost-effectiveness in healthcare: history of the $50,000 per QALY threshold","volume":"8","author":"Grosse","year":"2008","journal-title":"Expert Rev Pharmacoecon Outcomes Res"},{"key":"10.1016\/j.sapharm.2010.12.004_bib28","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1177\/135965359900400105","article-title":"Quality of life outcomes of saquinavir, zalcitabine and combination saquinavir plus zalcitabine therapy for adults with advanced HIV infection with CD4 counts between 50 and 300 cells\/mm3","volume":"4","author":"Revicki","year":"1999","journal-title":"Antivir Ther"},{"key":"10.1016\/j.sapharm.2010.12.004_bib29","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1097\/00002030-199905070-00016","article-title":"Quality of life outcomes of combination zalcitabine-zidovudine, saquinavir-zidovudine, and saquinavir-zalcitabine-zidovudine therapy for HIV-infected adults with CD4 cell counts between 50 and 350 per cubic millimeter. PISCES (SV14604) Study Group","volume":"13","author":"Revicki","year":"1999","journal-title":"AIDS"},{"key":"10.1016\/j.sapharm.2010.12.004_bib30","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1111\/j.1525-1497.2005.30402.x","article-title":"The association of health-related quality of life with survival among persons with HIV infection in the US","volume":"20","author":"Cunningham","year":"2005","journal-title":"J Gen Intern Med"},{"key":"10.1016\/j.sapharm.2010.12.004_bib31","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1177\/016327879802100207","article-title":"Changes in surrogate laboratory markers, clinical endpoints, and health-related quality of life in patients infected with the human immunodeficiency virus","volume":"21","author":"Chan","year":"1998","journal-title":"Eval Health Prof"},{"key":"10.1016\/j.sapharm.2010.12.004_bib32","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0885-3924(00)00245-1","article-title":"The use of highly active antiretroviral therapy (HAART) in patients with advanced HIV infection: impact on medical, palliative care, and quality of life outcomes","volume":"21","author":"Brechtl","year":"2001","journal-title":"J Pain Symptom Manage"},{"issue":"suppl 3","key":"10.1016\/j.sapharm.2010.12.004_bib33","doi-asserted-by":"crossref","first-page":"S136","DOI":"10.1097\/00126334-200212153-00010","article-title":"Depression is a risk factor for suboptimal adherence to highly active antiretroviral therapy","volume":"31","author":"Starace","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.sapharm.2010.12.004_bib34","doi-asserted-by":"crossref","first-page":"234","DOI":"10.2146\/ajhp070629","article-title":"Projecting future drug expenditures\u20142008","volume":"65","author":"Hoffman","year":"2008","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.sapharm.2010.12.004_bib35","first-page":"138","article-title":"Impact of new antihypertensive drugs on the healthcare utilization of hypertensive patients","volume":"1","author":"Ganguli","year":"2009","journal-title":"Am J Pharm Benefits"},{"key":"10.1016\/j.sapharm.2010.12.004_bib36","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1377\/hlthaff.26.3.880","article-title":"Do newer prescription drugs pay for themselves? A reassessment of the evidence","volume":"26","author":"Zhang","year":"2007","journal-title":"Health Aff (Millwood)"},{"key":"10.1016\/j.sapharm.2010.12.004_bib37","doi-asserted-by":"crossref","first-page":"397","DOI":"10.5034\/inquiryjrnl_42.4.397","article-title":"New cardiovascular drugs: patterns of use and association with non-drug health expenditures","volume":"42","author":"Miller","year":"2005","journal-title":"Inquiry"},{"key":"10.1016\/j.sapharm.2010.12.004_bib38","author":"Kaiser Family Foundation"}],"container-title":["Research in Social and Administrative Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551741110001713?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1551741110001713?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T09:06:14Z","timestamp":1761555974000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1551741110001713"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,3]]},"references-count":38,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012,3]]}},"alternative-id":["S1551741110001713"],"URL":"https:\/\/doi.org\/10.1016\/j.sapharm.2010.12.004","relation":{},"ISSN":["1551-7411"],"issn-type":[{"value":"1551-7411","type":"print"}],"subject":[],"published":{"date-parts":[[2012,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Does combining antiretroviral agents in a single dosage form enhance quality of life of HIV\/AIDS patients? A cost-utility study","name":"articletitle","label":"Article Title"},{"value":"Research in Social and Administrative Pharmacy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.sapharm.2010.12.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}